FDA unveils drugs to receive expedited review in support of ‘national priorities’

The Food and Drug Administration is announcing the first round of drugs that will receive drastically expedited reviews at the agency.
STAT

Inside FDA, career staffers describe how political pressure is influencing their work

Current and former FDA staff said the level of involvement of political officials in nitty-gritty regulatory matters is unprecedented.
Feedback